Earl, Patricia (NIAID)
Wyatt, Linda (NIAID)
The invention is fully developed.
The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful to insert the exogenous DNA into the genome of a vaccinia virus. Stability can be further enhanced by incorporating silent mutations that decrease the lengths of homopolynucleotide runs in the foreign gene.
- Efficient production of vaccinia-vectored vaccines for infectious diseases and other diseases such as cancer
- Efficient production of therapeutic proteins from vaccinia-vectored exogenous genes
- Enhancing stability of foreign genes in vaccinia-vectored constructs
- Increasing efficiency of vaccine production and gene expression